1,027 reports of this reaction
2.0% of all MYCOPHENOLIC ACID reports
#8 most reported adverse reaction
COVID 19 is the #8 most commonly reported adverse reaction for MYCOPHENOLIC ACID, manufactured by Novartis Pharmaceuticals Corporation. There are 1,027 FDA adverse event reports linking MYCOPHENOLIC ACID to COVID 19. This represents approximately 2.0% of all 51,116 adverse event reports for this drug.
MYCOPHENOLIC ACID has an overall safety score of 88 out of 100. Patients taking MYCOPHENOLIC ACID who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COVID 19 is a less commonly reported adverse event for MYCOPHENOLIC ACID, but still significant enough to appear in the safety profile.
In addition to covid 19, the following adverse reactions have been reported for MYCOPHENOLIC ACID:
The following drugs have also been linked to covid 19 in FDA adverse event reports:
COVID 19 has been reported as an adverse event in 1,027 FDA reports for MYCOPHENOLIC ACID. This does not prove causation, but indicates an association observed in post-market surveillance data.
COVID 19 accounts for approximately 2.0% of all adverse event reports for MYCOPHENOLIC ACID, making it a notable side effect.
If you experience covid 19 while taking MYCOPHENOLIC ACID, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.